Oscar R. Leeuwenkamp
Geneve, GE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset.
Journal: Current medical research and opinion
Published: April 14, 2022
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 23, 2021
Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities.
Journal: PharmacoEconomics - open
Published: June 05, 2021
Corrigendum to "Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis" [Cancer Treatm. Rev. 93 (2021) 102141].
Journal: Cancer treatment reviews
Published: April 15, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 10, 2020
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 10, 2020
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
Journal: Cancer treatment reviews
Published: October 13, 2020
Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study.
Journal: EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]
Published: October 13, 2020
Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France.
Journal: Journal of medical economics
Published: September 29, 2020
Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden.
Journal: World journal of clinical cases
Published: July 08, 2020
Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.
Journal: World journal of gastroenterology
Published: March 09, 2020
Last Updated: 09/26/2026